BLU PATENT V 2.5% S.A.L.F. (medical device)

La metoclopramide stimola e coordina la motilità del tratto superiore dell’apparato gastroenterico, senza modificare la secrezione gastrica, pancreatica e biliare.Il suo meccanismo d’azione è complesso, essendo il farmaco antagonista competitivo dei recettori D1 e D2 (dopamina) e dei recettori 5-HT3 (serotonina), nonché agonista aspecifico dei recettori 5-HT4 coinvolti nella stimolazione dei neuroni colinergici enterici. Ha quindi attività procinetica intestinale, indipendente dall’innervazione vagale ma abolita da atropina e altri antagonisti muscarinici.Essa determina un aumento del tono e dell’ampiezza delle contrazioni gastroduodenali e, in misura progressivamente ridotta in senso distale, un incremento coordinato dei movimenti propulsivi del digiuno, dell’ileo e del colon, con una progressione periferica del contenuto endoluminale. Aumenta ancora il tono della muscolatura del terzo medio e inferiore dell’esofago e quindi la pressione a livello dello sfintere, rilasciando nel contempo piloro e bulbo duodenale. Queste azioni si traducono in un accelerato svuotamento gastrico e in una diminuzione del reflusso dal duodeno nello stomaco e nell’esofago. Confezionamento: Metoclopramide - astuccio 5 fiale da 2ml ,10mg/2ml.

Dopamine acts as an agonist on specific dopamine receptors and on alpha and beta adrenergic receptors. It decreases peripheral resistance and causes mesenteric and renal vasodilation. It increases renal blood flow, glomerular filtration and urinary flow. As regards the heart, dopamine causes an increased inotropism. It differs from noradrenaline in the action on the region of the kidneys and from isoproterenol, as it does not increase the heart rate. The knowledge about cardiovascular activities of dopamine involving the activation of alpha and beta adrenergic receptors, as well as dopaminergic receptors, allows to better modulate the amine infusion, which, depending on the dose, can give effects of vasoconstriction or vasodilation, cardiac stimulation, inhibition of the increase in heart rate, diuresis, natriuresis and inhibition of aldosterone circulation. SALF is also committed to the development of two new concentrations, 200mg/5ml and 400mg/5ml.

The solution is intended for perfusion and

hypothermic preservation of kidney, liver and

pancreas.

The solution kept bewween at 2° and 6° C (36°

-43° F) is used to spray the isolated organ

immediately before or immediately after its

removal from the dead donor or immediately

after its removal from the living donor.

The solution is then left in the vessels of

the organ during hypothermic storage and

transport. The solution should be used for the

cold storage of the organ and it is not suitable

for the hypothermic preservation with a

continuous machine perfusion.

The device can be used only by medical staff

properly trained to its use, in accordance with

established operating protocols.

AVAILABLE IN THE FOLLOWING

PACKAGING:

Servator B

- Box containing 10 bags of 1000 ml.

- Box containing 5 bags of 2000 ml.

SHELF LIFE

24 months

PHYSICAL PROPERTIES:

The solution is clear and colorless or light

yellow.

The solution has a calculated osmolarity

of about 320 mosmol / l.

pH: 7.1 to 7.5 at 20 ° C.

The final concentration of sodium ions

is 29 mEq / l, of potassium ions is 125 mEq / l.

Pharmacotherapeutic group: Diuretics with a

major diuretic action.

Furosemide, a synthesis saluretic agent, causes

an increase in water and sodium elimination,

even in cases in which the glomerular filtration

is very limited.

The natriuretic effect is dose-dependent,

therefore, furosemide allows to obtain a guided

diuresis; instead, the urinary excretion of potassium

is significantly limited. As a result, the

sodium-potassium ratio is extremely favorable.

The diuretic effect following an oral administration

begins within the first hour and lasts 4-6

hours; by intravenous administration the effect

occurs within few minutes and lasts about 2

hours, while by intramuscular administration

the effect occurs a few minutes later, but the

duration of the action is longer.

PACKAGING:

Furosemide S.A.L.F. 250 mg/25 ml

solution for injection - 5 x 25 ml

vials A.I.C. 030671046 (Italian MA)

Furosemide S.A.L.F. 20 mg/2 ml

solution for injection - 5 x 2 ml

ampoules A.I.C. 030671010 (Italian MA)

A CENTURY OF GOOD SOLUTIONS